Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Operating Leases (2020 - 2026)

Neuroone Medical Technologies filings provide 7 years of Operating Leases readings, the most recent being $92361.0 for Q1 2026.

  • On a quarterly basis, Operating Leases fell 55.38% to $92361.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $92361.0, a 55.38% decrease, with the full-year FY2025 number at $143148.0, down 26.36% from a year prior.
  • Operating Leases hit $92361.0 in Q1 2026 for Neuroone Medical Technologies, down from $110374.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $272405.0 in Q4 2022 to a low of $20982.0 in Q4 2023.
  • Median Operating Leases over the past 5 years was $204934.0 (2022), compared with a mean of $179536.7.
  • Biggest five-year swings in Operating Leases: crashed 92.3% in 2023 and later surged 1031.34% in 2024.
  • Neuroone Medical Technologies' Operating Leases stood at $272405.0 in 2022, then crashed by 92.3% to $20982.0 in 2023, then surged by 1031.34% to $237377.0 in 2024, then tumbled by 53.5% to $110374.0 in 2025, then dropped by 16.32% to $92361.0 in 2026.
  • The last three reported values for Operating Leases were $92361.0 (Q1 2026), $110374.0 (Q4 2025), and $143148.0 (Q3 2025) per Business Quant data.